Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Getelman

Sports Medicine Van Nuys, CA Medical Doctor

NPI 1275569832 CMS profile 854652

6815 Noble Ave, Van Nuys, CA 91405

Open in the dashboard

General payments

$279,714

285 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$19,633

2 holdings reported · through program year 2025

Through program year 2025, Mark Getelman of Van Nuys, CA is reported in the CMS Open Payments database as having received $279,714 across 285 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $19,633 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,063 33
2024 General $26,596 36
2023 General $41,455 42
2022 General $32,640 30
2021 General $52,749 49
2020 General $71,015 44
2019 General $43,197 51
2024 Ownership $19,633 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Getelman
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Mark Getelman were reported at $12,063. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Mark Getelman Sports Medicine median Middle half National median
2019 $43,197 $1,176 $199–$4,249 $163
2020 $71,015 $708 $96–$2,890 $114
2021 $52,749 $1,213 $152–$3,994 $132
2022 $32,640 $1,230 $159–$3,998 $149
2023 $41,455 $584 $146–$2,836 $160
2024 $26,596 $628 $163–$3,168 $164
2025 $12,063 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $168,730 81 payments
  2. DePuy Synthes Products, Inc. $79,841 45 payments
  3. Zimmer Biomet Holdings, Inc. $13,023 19 payments
  4. Maruho Medical Inc. $8,972 8 payments
  5. Pristine Surgical LLC $5,000 1 payment
  6. DePuy Synthes Sales Inc. $2,665 74 payments
  7. Smith+Nephew, Inc. $346 10 payments
  8. Linvatec Corporation $252 5 payments
  9. Electronic Waveform Lab, Inc. $226 25 payments
  10. SPR Therapeutics, Inc $185 2 payments
  11. Other $474 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $249,702 99 payments
  2. Royalty or License $19,796 12 payments
  3. Food and Beverage $6,373 159 payments
  4. Travel and Lodging $3,844 15 payments
Products named General payments · program years 2019–2025
  1. VAPR Sports Surgical $95,828 26 payments
  2. HEALIX KNOTLESS PEEK $34,510 24 payments
  3. HEALIX $26,473 11 payments
  4. GRYPHON $19,275 10 payments
  5. VISUALIZATION $18,225 1 payment
  6. Accessories $5,250 1 payment
  7. Summit Arthroscope $5,000 1 payment
  8. VAPR Sports Surgical $1,980 1 payment
  9. ITTO CSP $1,900 3 payments
  10. DYNACORD $1,251 11 payments
  11. Other $7,482 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

261

Median for Orthopedic Surgery: 203

Drug cost

$884

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 226 $683
Methylprednisolone Generic 21 $124
Diclofenac Sodium Generic 14 $77

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$147,006

Of which drugs: $1,316

Medicare patients

444

Average age 73

Services billed

1,676

229 women, 215 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 72%
High blood pressure 63%
Ischemic heart disease 33%
Diabetes 21%
Osteoporosis 19%
Depression 16%
Cancer 15%
Chronic kidney disease 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 31 175 $979
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 43 192 $149

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record